Gilead Sciences Inc. (GILD)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

333 LAKESIDE DR FOSTER CITY, CA 94404

Gilead Sciences is a biopharmaceutical company. Co.'s product portfolio includes Truvada, Atripla, Viread and Emtriva for the treatment of human immunodeficiency virus infection; Hepsera and Viread for the treatment of hepatitis B; AmBisome for the treatment of fungal infections; Letairis for the treatment of pulmonary arterial hypertension; Ranexa for the treatment of angina; Vistide for the treatment of cytomegalovirus retinitis; and Cayston for cystic fibrosis patients with Pseudomonas aeruginosa. Co. owns or have rights to a range of trademarks, copyrights and trade names, such as, among others, GILEAD, GILEAD SCIENCES, TRUVADA, VIREAD, and HEPSERA.

Data as of 2020-11-22
Market Cap75.35 Billion Shares Outstanding1.254 Billion Avg 30-day Volume9.958 Million
P/E Ratio62.0 Dividend Yield4.525 EPS0.97
Price/Sales4.424 Price cash flow ratio8.6 Price free cash flow ratio-38.7
Book Value13.92 Price to Tangible Book193.7 Alpha-0.01
Short Interest Ratio % Short Interest to Float R-squared0.109816
BETA0.529687 52-week High/Low85.97 / 57.04 Stddev0.067358
View SEC Filings from GILD instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 24 38 -36.84% 8 (0.53%) 8 (0.52%) 0.0%
Funds Holding: 1467 1576 -6.92% 247 (16.24%) 265 (17.2%) -6.79%
13F shares: 960.018 Million 978.459 Million -1.88% 102.554 Million 103.105 Million -0.54%
% Ownership 76.5733 78.0442 -1.88% 8.1799 8.2239 -0.54%
New Positions: 109 155 -29.68% 30 39 -23.08%
Increased Positions 568 612 -7.19% 83 87 -4.6%
Closed Positions 178 159 11.95% 43 40 7.5%
Reduced Positions 618 665 -7.07% 109 113 -3.54%
Total Calls 21.815 Million 24.818 Million -12.1% 5.328 Million 5.447 Million -2.19%
Total Puts 29.687 Million 27.087 Million 9.6% 11.443 Million 11.179 Million 2.37%
PUT/CALL Ratio 1.36 1.09 24.77% 2.15 2.05 4.88%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding GILD (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding GILD BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

9.6 Thousand total shares from 5 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

DICKINSON ANDREW D EVP, CHIEF FINANCIAL OFFICER

  • Officer
16,286 2020-11-10 6

PARSEY MERDAD CHIEF MEDICAL OFFICER

  • Officer
2,685 2020-11-10 3

WILFONG DIANE E. SVP, CONTROLLER & CAO

  • Officer
14,201 2020-11-10 7

MERCIER JOHANNA CHIEF COMMERCIAL OFFICER

  • Officer
17,906 2020-11-03 3

WELTERS ANTHONY

  • Director
0 2020-10-22 2

WHITLEY RICHARD JAMES

  • Director
31,122 2020-10-01 6

LOFTON KEVIN E

  • Director
0 2020-09-29 6

RODRIGUEZ JAVIER

  • Director
0 2020-06-23 4

KRAMER KELLY A.

  • Director
0 2020-05-06 1

BARTON JACQUELINE K

  • Director
0 2020-05-06 1

HORNING SANDRA

  • Director
0 2020-05-06 3

WOLD OLSEN PER

  • Director
100,124 2020-05-05 2

WILSON GAYLE E

  • Director
129,052 2020-05-05 2

MANWANI HARISH

  • Director
3,718 2020-05-05 1

PLETCHER BRETT A EVP,CORP AFFAIRS & GEN COUNSEL

  • Officer
14,644 2020-05-05 7

COGAN JOHN FRANCIS

  • Director
54,860 2020-05-04 9

O'DAY DANIEL PATRICK CHAIRMAN & CEO

  • Officer
  • Director
0 2020-03-10 3

HAMILL LAURA EVP, WORLDWIDE COMMERCIAL OPS

  • Officer
6,340 2019-05-08 0

ALTON GREGG H CHIEF PATIENT OFFICER

  • Officer
58,046 2019-02-15 0

WASHINGTON ROBIN L EVP, CFO

  • Officer
138,943 2019-02-12 0

MARTIN JOHN C

  • Director
2,887,225 2019-02-06 0

MCHUTCHISON JOHN G CHIEF SCIENTIFIC OFF/HEADR&D

  • Officer
37,828 2019-02-06 0

MILLIGAN JOHN F PRESIDENT AND CEO

  • Officer
  • Director
1,574,306 2018-11-27 0

MOORE NICHOLAS G

  • Director
0 2018-03-29 0

BISCHOFBERGER NORBERT W EVP, R&D AND CSO

  • Officer
2,337,402 2018-02-15 0

YOUNG KEVIN CHIEF OPERATING OFFICER

  • Officer
25,612 2018-02-15 0

MEYERS JAMES R EVP WORLDWIDE COMMERCIAL OPS

  • Officer
No longer subject to file 2018-02-15 0

MADIGAN JOHN W

  • Director
18,548 2017-05-09 0

CARTER PAUL RUTHERFORD EVP COMMERCIAL OPS

  • Officer
62,305 2016-08-01 0

DAVIGNON ETIENNE

  • Director
838,652 2016-05-06 0

HILLS CARLA A

  • Director
39,285 2016-05-06 0

DENNY JAMES M

  • Director
281,158 2012-11-28 0

METZA KRISTEN SVP, HUMAN RESOURCES

  • Officer
No longer subject to file 2012-11-01 0

MOORE GORDON EARLE

  • Director
1,063,839 2012-08-14 0

BERG PAUL

  • Director
No longer subject to file 2011-05-11 0

LANGE LOUIS G

  • FORMER EVP CARDIO THERAPEUTICS
No longer subject to file 2009-06-01 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

PARSEY MERDAD - Officer CHIEF MEDICAL OFFICER

2020-11-12 17:44:42 -0500 2020-11-10 M 5,101 a 5,101 direct 0.8335 -0.784 0.8335 2 -0.784 6

DICKINSON ANDREW D - Officer EVP, CHIEF FINANCIAL OFFICER

2020-11-12 17:50:56 -0500 2020-11-10 F 1,399 $60.62 d 16,286 direct 0.8335 -0.784 0.8335 2 -0.784 6

WILFONG DIANE E. - Officer SVP, CONTROLLER & CAO

2020-11-12 17:34:17 -0500 2020-11-10 M 657 d 17,971 direct

WILFONG DIANE E. - Officer SVP, CONTROLLER & CAO

2020-11-12 17:34:17 -0500 2020-11-10 M 657 a 14,812 direct 0.8335 -0.784 0.8335 2 -0.784 6

PARSEY MERDAD - Officer CHIEF MEDICAL OFFICER

2020-11-12 17:44:42 -0500 2020-11-10 M 5,101 d 24,019 direct

DICKINSON ANDREW D - Officer EVP, CHIEF FINANCIAL OFFICER

2020-11-12 17:50:56 -0500 2020-11-10 M 1,913 d 32,118 direct

DICKINSON ANDREW D - Officer EVP, CHIEF FINANCIAL OFFICER

2020-11-12 17:50:56 -0500 2020-11-10 M 1,913 a 17,685 direct 0.8335 -0.784 0.8335 2 -0.784 6

WILFONG DIANE E. - Officer SVP, CONTROLLER & CAO

2020-11-12 17:34:17 -0500 2020-11-10 M 773 d 18,628 direct

WILFONG DIANE E. - Officer SVP, CONTROLLER & CAO

2020-11-12 17:34:17 -0500 2020-11-10 M 773 a 14,155 direct 0.8335 -0.784 0.8335 2 -0.784 6

PARSEY MERDAD - Officer CHIEF MEDICAL OFFICER

2020-11-12 17:44:42 -0500 2020-11-10 F 2,416 $60.62 d 2,685 direct 0.8335 -0.784 0.8335 2 -0.784 6

DICKINSON ANDREW D - Officer EVP, CHIEF FINANCIAL OFFICER

2020-11-12 17:50:56 -0500 2020-11-10 M 1,133 d 34,031 direct

DICKINSON ANDREW D - Officer EVP, CHIEF FINANCIAL OFFICER

2020-11-12 17:50:56 -0500 2020-11-10 M 1,133 a 15,772 direct 0.8335 -0.784 0.8335 2 -0.784 6

WILFONG DIANE E. - Officer SVP, CONTROLLER & CAO

2020-11-12 17:34:17 -0500 2020-11-10 F 611 $60.62 d 14,201 direct 0.8335 -0.784 0.8335 2 -0.784 6

MERCIER JOHANNA - Officer CHIEF COMMERCIAL OFFICER

2020-11-05 17:16:40 -0500 2020-11-03 A 26,270 a 30,188 direct -0.0339 2.5648 2.624 3 -0.0339 2

MERCIER JOHANNA - Officer CHIEF COMMERCIAL OFFICER

2020-11-05 17:16:40 -0500 2020-11-03 F 12,282 $58.83 d 17,906 direct -0.0339 2.5648 2.624 3 -0.0339 2

WELTERS ANTHONY - Director

2020-10-26 19:12:45 -0400 2020-10-22 A 1,368 a 1,368 direct

WELTERS ANTHONY - Director

2020-10-26 19:12:45 -0400 2020-10-22 A 7,718 a 7,718 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments